Prompt engineering is the new power move. Human inquiry is the new blind spot. One of these is costing you more than you know.

Databricks, Snowflake, Amazon Redshift, Google BigQuery, and Microsoft Fabric – to see how they address rapidly evolving ...

Modernize legacy BI without disruption. Refactor business logic into a governed semantic layer while keeping dashboards ...

The Patriots offensive line should be a target for New England in this year’s draft, especially after the unit being upended by the Seattle Seahawks in Super Bowl 60. In ESPN’s latest mock Draft, ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. What else is she supposed to do except ...

After the Alabama Crimson Tide’s season came to an end, Kalen DeBoer decided to move on from offensive line coach Chris Kapilovic. Kapilovic had been with the program for two seasons, but after some ...

Adobe announced a multi-year partnership with Runway in December 2025, integrating Runway's Gen-4.5 AI video generation model directly into Adobe Firefly. The partnership makes Adobe Runway's ...

Kevin Stefanski took the Atlanta Falcons head coaching job on Saturday night and he's already started putting together his staff. According to NFL Network insider Mike Garafolo, the Falcons are ...

Meta Platforms Inc. has agreed to acquire Singapore-based AI startup Manus, which makes an artificial intelligence agent that it sells to small and medium-sized businesses. The deal is part of a ...

This repository contains the experimental artifacts used in the evaluation of Large Language Models (LLMs) for Text-to-SQL translation, as described in the associated manuscript. The materials ...

AI chatbots learn more about us with every interaction. They can therefore tease out patterns in our thinking. They're no substitute for a friend or therapist, though. "You're the kind of person who ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...